Glucose metabolism in non-diabetic patteate with stable coronary artery disease;Metabolismo da glucose em doentes não diabéticos com doença coronária estável

Revista Portuguesa de Cardiologia

Volumn 25, Issue 1, 2006, Pages 39-53

  Ferreira Santos, José ^a,b   Almeida, Manuel ^a   Ferreira, Jorge ^a   Gonçalves, Pedro ^a   Raposo, Luís ^a   Teles, Rui ^a   Branco, João ^a   Catroga, Teresa ^a   Pereira Machado, Francisco ^a   Silva, Aniceto ^a  

^a HOSPITAL DE SANTA CRUZ   (Portugal)

^b HOSPITAL DE SÃO BERNARDO   (Portugal)

Author keywords

Coronary disease; Diabetes mellitus; Glucose intolerance; Glucose tolerance test

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE CLASSIFICATION; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULINEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CORONARY ARTERIOSCLEROSIS; FEMALE; GLUCOSE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 33645468594     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dunstan D, Zimmet P, Welborn T et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care, 2002;25:829-34.
2. Kannel W, McGee D. Diabetes and cardiovascular risk factors in the Framingham Study. JAMA 1978;38:46-51.
3. Stamler J. Vaccaro O, Neaton J. Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993:16(2):434-44.
4. Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J 2004;147(2):239-45.
5. Mukamal KJ, Nesto RW, Cohen MC et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001;24(8):1422-7.
6. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26(3):688-96.
7. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447-53.
8. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-7.
9. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care. 1999;22(5):696-9.
10. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-40.
11. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990 Jun 6;263(21):2893-8.
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004:27(Suppl 1):S5-S10.
13. Muhlestein J, Anderson J, Horne B et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J, 2003;146(2):351-8.
14. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J, 2004;25(22):1990-7.
15. Yanase M, Takatsu F, Tagawa T, et al. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J, 2004;68(1):47-52.
16. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol, 1995;26(1):57-65.
17. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 2003;24(17):1601-10.
18. Knowler W, Barret-Connor E, Fowler S et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002;356:393-403.
19. Norhammar A, Tenerz A, Nilsson G. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002;359(9324):2140-4.
20. Qiao Q, Pyorala M, Nissinen A et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J, 2002;23(16):1267-75.
21. Barrett-Connor E. The oral glucose tolerance test, revisited. Eur Heart J. 2002;23(16):1229-31.
22. Honora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 2000;23(1):57-63.
23. Grundy S, Brewer B, Cleeman J et al. Definitions of Metabolic Syndrome. Circulation, 2004;109:433-438
24. Califf R, Phillips H, Hindman M et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 1985;5(5):1055-63.
25. Graham M, Faris P, Ghali W et al. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 2001;142(2):254-61.
26. Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J, 2004;25(21):1880-90.
27. Peters A, Davidson M, Schriger D, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels: Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996;276:1246-52.
28. Aguilar D, Solomon S, Kober L et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation, 2004;110(12):1572-8.
29. Lakka H, Laaksonen D, Lakka T et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709-16.
30. Malik S, Wong N, Franklin S et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110(10):1245-50.